Table 2.
Conditioning and Post-HCT Outcomes
| Variable | Cases* (n = 60)
|
Controls* (n = 166)
|
P | ||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Age at HCT, years | |||||
| Mean | 45.7 | 45.5 | |||
| SD | 13.7 | 13.0 | |||
| Donor source, autologous transplant | 41 | 68.3 | 114 | 68.7 | |
| Time from diagnosis to HCT, years | |||||
| Mean | 2.6 | 1.7 | .10 | ||
| SD | 4.0 | 2.6 | |||
| Body mass index at HCT, kg/m2 | |||||
| Mean | 28.4 | 26.2 | .01 | ||
| SD | 7.0 | 5.2 | |||
| Conditioning regimen | |||||
| Cyclophosphamide | 45 | 75.0 | 125 | 75.3 | .96 |
| Etoposide | 42 | 70.0 | 111 | 66.9 | .66 |
| Total-body irradiation | 39 | 65.0 | 109 | 65.7 | .93 |
| Melphalan | 13 | 21.7 | 29 | 17.5 | .47 |
| Carmustine | 12 | 20.0 | 21 | 12.7 | .17 |
| Busulfan | 8 | 13.3 | 30 | 18.1 | .40 |
| Post-HCT comorbidity by type | |||||
| Hypertension | 24 | 40.0 | 24 | 14.5 | < .01 |
| Renal Insufficiency | 14 | 23.3 | 11 | 6.6 | < .01 |
| Chronic lung disease | 12 | 20.0 | 13 | 7.8 | .01 |
| Diabetes | 12 | 20.0 | 9 | 5.4 | < .01 |
| Thyroid, hyper/hypo | 6 | 10.0 | 18 | 10.8 | .86 |
| Dyslipidemia | 4 | 6.7 | 17 | 10.2 | .41 |
| Post-HCT comorbidity by number | |||||
| No comorbidity | 21 | 35.0 | 104 | 62.6 | |
| 1 comorbidity | 21 | 35.0 | 39 | 23.5 | < .01 |
| ≥ 2 comorbidities | 18 | 30.0 | 23 | 13.9 | |
Abbreviations: HCT, hematopoietic cell transplantation; SD, standard deviation.
*
Group matching criteria included age at HCT (± 5 years), type of HCT (autologous v allogeneic), year of HCT (± 2 years), and duration of follow-up.